1. Karhuvaara, S., Simojoki, K., Virta, A., Rosberg, M., Loyttyniemi, E., Nurminen, T., Kallio, A., Makela, R. (2007). Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcoholism Clinical and Experimental Research, 31(7), 1179-87.
To purchase this paper click here:

2. Soyka, M., & Rösner. (2010). Nalmefene for treatment of alcohol dependence. Expert Opinion on Investigational Drugs, 19(11), 1451-1459.
To purchase this paper click here:

3. Fuxe, K., Marcellino, D., Genedani, S., & Agnati, L. (2007). Adenosine A2A receptors, dopamine D2 receptors and their interactions in Parkinson’s disease. Movement Disorders, 22(14), 1990-2017.
To purchase this paper click here:

4. Black, K. J., Jonathan, M., Campbell, M. C., Gusnard, D, A., & Bandak, S, l. (2010). Quantification of indirect pathway inhibition by the adenosing A2a antagonistic SYN115 in Parkinson disease. The Journal of Neuroscience, 30(48), 16284-16292.
To view the full paper click here:

5. Upton, N., Chuang, T. T., Hunter, A, J., & Virley, D. J. (2008). 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics, 5(3), 458-469.
To view the full paper click here:

6. Shank, J. R., Ventura, R., Puglisi-Allegra, S., Alcaro, A., Cole, C. D., Liles, L. C., Seema, P., & Weinshenker, D. (2006). Dopamine -Hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharacology, 31, 2221-2230.
To view the full paper click here:

7. Stanley, W. C., Bonhaus, L. B., Johnson, L. G., Lee, K., Porter, S., Walker, K., Martinez, G., Eglen, R. M., Whiting, R. L., & Hegde, S. S. (1997). Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. British Journal of Pharmacology, 121(8), 1803-1809.
To view the full paper click here:

8. Weinshenker, D., & Schroeder, J. P. (2007). There and back again: A tale of norepinephrine and drug addiction. Neuropsychopharmacology, 32, 1433-1451.
To view the full paper click here:

9. Kluz, A., Mahaney-Price, A., Muhlstadt, K. (n.d.). A randomized, placebo-controlled trial of the dopamine-ß-Hydroxylase (DBH) inhibitor, nepicastat, for the treatment of PTSD in OIF/OEF veterans.
To view the poster, click here 

10. Growdon, J. H., Melamed, E., Logue, M., Hefti, F., Wurtman, R. J. (1982). Effects of oral l-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with parkinson’s disease. Life Sciences, 30, 827-832.
To view the full paper click here:

11. Melamed, E., Hefti, F., & Wurtman, R. J. (1980). Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions. (dihydroxyphenylacetic acid/homovanillic acid/striatum). Medical Sciences, 77(7), 4305-4309.
To view the full paper click here:

12. McKiernan, P. J. (2006). Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs, 66(6), 743-750.
To purchase this paper click here:

 

---------------------------------------

Updated October 12, 2011